Ascletis Pharma Joins Hong Kong-Mainland Stock Connect Programs

Key Facts

In a move reflecting the ongoing integration of Asian financial markets, Ascletis Pharma has announced the inclusion of its ordinary shares in the Stock Connect programs. According to reports, the shares became eligible for trading through both the Shanghai-Hong Kong and Shenzhen-Hong Kong channels effective September 7, 2026. This inclusion follows regulatory updates to the list of eligible securities for the cross-border investment channel between mainland China and Hong Kong.

The mutual stock market access mechanism enables mainland Chinese investors to trade the company's Hong Kong-listed shares through their local securities firms. Per analyst data, this step is expected to increase liquidity and broaden the investor base by accessing mainland capital. Ascletis utilizes proprietary AI-assisted drug discovery and oral peptide transport technologies to develop candidates for chronic weight management and diabetes.

Based on available market data, specific price levels for the instrument (1672.HK) are currently unavailable as of the September 7, 2026 snapshot. Investors will be watching for shifts in daily trading volume resulting from this new capital access. On the macroeconomic front, recent data from China showed the Manufacturing PMI reached 51.5 on September 1, 2026, suggesting a stable regional operating environment for biotech firms.